Furthermore, we observed that PTPN1 had good predictive efficacy for predicting 1-, 3-, and 5-year DSS in patients with KICH, UVM, LGG, GBM, BLCA, and BRCA. This evidence concerns the gene PTPN1 and bladder transitional cell carcinoma.